Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma

BACKGROUND: The sensitivity of myelocytomatosis oncogene (MYC) amplified medulloblastoma to class I histone deacetylase (HDAC) inhibition has been shown previously; however, understanding the underlying molecular mechanism is crucial for selection of effective HDAC inhibitors for clinical use. The a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Ecker, Jonas, Thatikonda, Venu, Sigismondo, Gianluca, Selt, Florian, Valinciute, Gintvile, Oehme, Ina, Müller, Carina, Buhl, Juliane L, Ridinger, Johannes, Usta, Diren, Qin, Nan, van Tilburg, Cornelis M, Herold-Mende, Christel, Remke, Marc, Sahm, Felix, Westermann, Frank, Kool, Marcel, Wechsler-Reya, Robert J, Chavez, Lukas, Krijgsveld, Jeroen, Jäger, Natalie, Pfister, Stefan M, Witt, Olaf, Milde, Till
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906057/
https://ncbi.nlm.nih.gov/pubmed/32822486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa191
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares